Home › Funds › Nicholas Investment Partners, LP › ELVN

Nicholas Investment Partners, LP position in ELVN

ENLIVEN THERAPEUTICS INC · Health Care

Nicholas Investment Partners, LP reported holding 549,190 shares of ELVN (ENLIVEN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$25.2M, representing 1.89% of its reported portfolio and ranking #4 among its reported holdings. Nicholas Investment Partners, LP has disclosed ELVN holdings in 6 of the last 10 reported quarters, going back to Q2 2024.

Latest position (Q3 2026)549.19K sh
Reported value held$25.17M
Portfolio Weight1.89%
First reportedQ2 2024
Last changeAdd
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Nicholas Investment Partners, LP's ELVN position evolved

Nicholas Investment Partners, LP first disclosed a stake in ELVN in Q2 2024 at 56,072 shares (US$1.3M). The position peaked in Q3 2026 at 549,190 shares, worth US$25.2M. Across 6 filings, Nicholas Investment Partners, LP increased the stake 3 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 549,190 shares valued at US$25.2M — an increase of 157,661 shares quarter over quarter.. Notable position changes include a 210% increase in Q3 2024 (shares fell 12% over the following quarter), a 114% increase in Q2 2026 (shares fell 10% over the following quarter), a 40% increase in Q3 2026 (shares rose 6% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2024 56.07K $1.31M New
Q3 2024 173.75K $4.44M Add
Q4 2024 157.63K $3.55M Reduce
Q1 2026 182.73K $7.16M New
Q2 2026 391.53K $19.87M Add
Q3 2026 549.19K $25.17M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ELVN and 13F data

ELVN (ENLIVEN THERAPEUTICS INC) is a Health Care company. 61 other funds we track also report a position in ELVN — the largest reported positions include ORBIMED ADVISORS LLC (US$343.9M), Polar Capital Holdings Plc (US$294.5M), Vestal Point Capital, LP (US$203.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ELVN

All ELVN fund holders →

FAQ

How long has Nicholas Investment Partners, LP held ELVN?

Nicholas Investment Partners, LP has disclosed ELVN holdings in 6 of the last 10 reported quarters, going back to Q2 2024.

What is Nicholas Investment Partners, LP's current position in ELVN?

As of Q3 2026, Nicholas Investment Partners, LP holds 549.19K shares of ELVN (ENLIVEN THERAPEUTICS INC), valued at $25.17M, representing 1.89% of its reported portfolio and ranking #4.

Has Nicholas Investment Partners, LP been buying or selling ELVN?

In the latest 13F filing (Q3 2026), Nicholas Investment Partners, LP increased its position in ELVN. The position peaked in Q3 2026 at 549.19K shares.

Which other funds hold ELVN?

Other major institutional holders of ELVN include ORBIMED ADVISORS LLC, Polar Capital Holdings Plc, Vestal Point Capital, LP, among 61 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.